Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates  by McBurney, Sean P. et al.
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We  describe  the  preclinical  development  of  a  dengue  virus  vaccine  targeting  the  dengue  virus  serotype
2  (DENV2)  envelope  domain  III (EDIII).  This study  provides  proof-of-principle  that  a dengue  EDIII  protein
scaffold/DNA  vaccine  can  protect  against  dengue  challenge.  The  dengue  vaccine  (EDIII-E2)  is  composed
of both  a protein  particle  and  a DNA  expression  plasmid  delivered  simultaneously  via intramuscular
injection  (protein)  and gene  gun  (DNA)  into  rhesus  macaques.  The  protein  component  can  contain  a
maximum  of  60  copies  of  EDIII  presented  on a multimeric  scaffold  of Geobacillus  stearothermophilus  E2
proteins.  The  DNA  component  is  composed  of  the  EDIII  portion  of  the envelope  gene cloned  into  an
expression  plasmid.  The  EDIII-E2  vaccine  elicited  robust  antibody  responses  to DENV2,  with  neutralizing
antibody  responses  detectable  following  the ﬁrst  boost  and  reaching  titers  of  greater  than  1:100,000
following  the  second  and  ﬁnal boost.  Vaccinated  and  naïve  groups  of  macaques  were  challenged  with
DENV2.  All  vaccinated  macaques  were  protected  from  detectable  viremia  by infectious  assay,  while  naïve
animals had  detectable  viremia  for  2–7 days  post-challenge.  All  naïve  macaques  had  detectable  viral
RNA  from  day  2–10 post-challenge.  In the  EDIII-E2  group,  three  macaques  were  negative  for viral RNA
and  three  were  found  to have  detectable  viral  RNA  post  challenge.  Viremia  onset  was  delayed  and  the
duration  was  shortened  relative  to  naïve  controls.  The  presence  of  viral  RNA  post-challenge  corresponded
to  a 10–30-fold  boost  in  neutralization  titers  28  days  post  challenge,  whereas  no boost  was  observed  in
the  fully  protected  animals.  Based  on  these  results,  we  determine  that  pre-challenge  50%  neutralization
titers  of >1:6000  correlated  with  sterilizing  protection  against  DENV2  challenge  in  EDIII-E2  vaccinated
macaques.  Identiﬁcation  of  the  critical  correlate  of protection  for the  EDIII-E2  platform  in  the  robust  non-
human primate  model  lays  the  groundwork  for further  development  of  a tetravalent  EDIII-E2  dengue
vaccine.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. IntroductionDENV is the most important arthropod-borne viral pathogen
f humans worldwide. There are four serotypes, DENV1-4, all of
hich cause a spectrum of illness ranging from classic dengue fever
∗ Corresponding author at: Department of Molecular Microbiology and Immunol-
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ortland, OR 97239, USA. Tel.: +1 503 494 2185.
E-mail address: messer@ohsu.edu (W.B. Messer).
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264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
to severe, potentially fatal disease characterized by hemorrhage
and hypotensive shock – dengue hemorrhagic fever and dengue
shock syndrome (DHF/DSS). Infection with one serotype leads to
a short-term broadly cross-reactive antibody response that wanes
over months to years to a protective immunity against only the
infecting serotype [1,2]. However, immunity to one DENV serotype
predisposes an individual to severe disease on infection by a dif-
ferent serotype through a process known as antibody-dependent
enhancement (ADE) of infection. ADE is thought to occur when
cross-reactive non-neutralizing antibodies from the ﬁrst infec-
tion bind heterotypic virus and facilitate antibody-virus complex
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. EDIII-E2/E2 DNA vaccine characterization. EDIII-E2 particles were charac-
terized for size, composition, and purity. (A) Transformed E. coli containing the
EDIII-E2 expression plasmid were induced and lysed. Protein lysates were loaded
into SDS-Page gels for visualization. 1. E2 pre-induction, 2. E2 induced, 3. EDIII-E2
pre-induction. 4. EDIII-E2 induced. One gel was stained for protein. Matching gels
were transferred to nitrocellulose and probed by western blot for E2 (red) and EDIII
(green), A merged ﬁgure is shown at the bottom of a showing the localization of
both the E2 and EDIII stains. (B) Puriﬁed EDIII-E2 particles were separated by SDS-
PAGE and then stained for protein. A previously puriﬁed EDIII-E2 sample is shown
in lane 1. Lanes 2 and 3 show column fractions that were combined for the overall
EDIII-E2 recombinant protein vaccine component. No E2wt was present. (C) 293T
cells were transformed with the EDIII DNA vaccine eluted from vaccination bullets.S.P. McBurney et al. / V
ptake via Fc- receptor-bearing host cells [3–6]. ADE is thought to
ead to higher levels of serum viremia and inﬂammatory cytokines
nd, ultimately, risk of severe disease [7]. DENV infects 400 million
eople annually (with 100 million symptomatic cases) and approx-
mately 3.6 billion people live in areas at risk of DENV transmission
8]. Given the global burden of DENV disease, there is an urgent
eed for a licensed DENV vaccine. While the most advanced vac-
ine to date, the Sanoﬁ CYD-TDV live attenuated vaccine (LAV) has
hown an overall efﬁcacy of 60.3% [9–12], protection appears biased
oward vaccinees who were DENV seropositive before ﬁrst vaccine
ose. Serotype speciﬁc protection also varied substantially, from
3.6% for DENV2 in vaccinees aged <9 yrs old to 81.9% against DENV-
 for vaccinees aged >9. These variable results are hypothesized to
e related to limited immunogenicity of the vaccine strains, poten-
ially driven by serotype immunodominance and LAV competition,
articularly in DENV naïve recipients.
Here we describe an alternate approach to LAVs, using protein
caffold/DNA-based DENV vaccine targeting the DENV envelope
lycoprotein (E) domain III (EDIII). The DENV E glycoprotein exists
s homo-dimers with 3 distinct domains – I, II, and III – that
re arranged in a ﬂat herringbone pattern with icosahedral sym-
etry [13]. When expressed as a recombinant polypeptide, EDIII
referentially folds into its native conformation [14] and has
een shown to elicit potently neutralizing antibodies that tar-
et tertiary epitopes displayed on wild-type virus [15,16]. While
ENV EDIII recombinant protein vaccines have been described in
he past 10 years, few have undergone immunogenicity trials in
on-human primates [17–25] with even fewer evaluating protec-
ion [18,21,23–25]. Those that have been evaluated in protection
tudies are all EDIII fusion proteins, with EDIII fused to DENV2
apsid protein [18], the P64K protein from Neisseria meningitidis
21,24,25], and Salmonella enterica ﬂagellin [23]. Fusion proteins
ere employed as EDIII carriers that are also immunostimulatory
ia innate immune pathways.
For this study recombinant DENV2 EDIII was  presented on a
rotein scaffold of the E2 protein, a subunit of the pyruvate dehy-
rogenase complex from Geobacillus stearothermophilus. Native E2
E2wt) monomers self-assemble into a 60 mer  pentagonal dodeca-
edral scaffold with icosahedral symmetry [26]. E2 can be modiﬁed
t the N-terminus by replacing E2 peripheral domains with exoge-
ous polypeptides, creating a novel E2 multimeric antigen display
ystem (E2DISP) [26,27] that can present up to 60 polypeptides
ithout negatively impacting the native folding of the E2 core.
e have previously explored the multimeric E2 protein scaffold
s an HIV vaccine platform [28–30] and these studies showed that
o-vaccination of DNA with E2 scaffolds displaying HIV envelope
pitopes improves both antibody responses and T cells [29,30].
his observation has also been observed using DNA combined with
ecombinant HIV trimeric gp140 envelope [31]. Here we show that
his DENV2 EDIII-E2/DNA vaccine was both highly immunogenic
nd conferred protection upon challenge with DENV2, demonstrat-
ng that a DNA and protein scaffold-based DENV vaccine may  be a
iable alternative to current DENV vaccine strategies.
. Materials and methods
.1. Animals and immunizations
Adult Macaca mulatta (rhesus macaques) were housed at the
regon National Primate Research Center (ONPRC) in Beaver-
on, OR. All procedures were performed according to protocols
pproved by the IACUC at OHSU. Six macaques were immunized
t weeks 0, 4, and 12 with 500 g of soluble EDIII-E2 particles
elivered intramuscularly formulated with 20% Adjuplex (Sigma)
djuvant along with EDIII and rhesus IL-12 DNA delivered epi-
ermally by Particle Mediated Epidermal Delivery (PMED) deviceLane 1 shows an EDIII-E2 particle as a control. Lanes 2 and 4 supernatant and 3 and 5
are  lysate from bullet transfected cells. (For interpretation of the references to color
in  this ﬁgure legend, the reader is referred to the web version of this article.)
(gene gun, XR-1 research model, PowderMed, Oxford, UK), via 1 mg
of 1 mM-size gold particles coated with 1.8 g of vaccine DNA and
0.2 g of IL-12 plasmid (2 g total) into 18 sites along the shaved
abdomen and upper thighs.
2.1.1. DNA vaccine gene gun cartridges
Plasmid pEMC* [32] including the oligonucleotide sequence
encoding the EDIII DNA encoding DENV serotype 2 strain 16681
E domain III (amino acid (aa) positions 297–399 on the DENV2
genome) was  precipitated onto 1 m diameter gold beads, and car-
tridges were prepared for delivery with the Powderject PMED gene
gun delivery device (Powderject Vaccines, Madison, WI).
2.1.2. Recombinant EDIII-E2 particles
The EDIII-E2 expression vectors were constructed from thep-
ETE2DISP plasmid [26] as previously described [30]. E2wt is
expressed from pETE2DISP without modiﬁcation. For EDIII-E2
expression, the oligonucleotide sequence encoding the serotype 2
DENV isolate 16681 E domain III (aa positions 297–399, positions
on the DENV2 strain 16681 E glycoprotein) was  cloned into the
pETE2DISP vector for expression of EDIII as an N-terminal fusion
to the E2 core scaffold (Fig. 1A) by PCR ampliﬁcation of strain
16681 clone plasmid using standard methods and the primers (D2-
ED3+) NNNNCCATGCCGATGTCATACTCTATGTGCACAGG and (D2-
ED3-)NNNNCCCGGGGCCGATAGAACTTCCTTTCTTAAAC containing
the restriction site XmaI. The PCR product and pETE2DISP vector
3 accine
w
R
2
s
b
E
i
o
a
T
O
I
c
b
T
3
e
o
F
g
w
(
a
t
w
l
c
c
t
S
E
E
w
a
t
i
a
w
a
o
E
u
i
r
h
p
2
w
I
r
p
w
w
4
s
m
i
w502 S.P. McBurney et al. / V
ere digested, ligated and transformed into BL21 (DE3) CodonPlus-
IPL competent cells (Stratagene).
.2. Expression, puriﬁcation and refolding of EDIII-E2 multimeric
caffolds
Methods and buffers used in puriﬁcation and refolding have
een described in detail previously [30]. The plasmids encoding
2wt and EDIII-E2 fusion protein was maintained and expressed
n BL21 (DE3) CodonPlus-RIPL cells (Stratagene). Cells were grown
vernight at 37 ◦C in Luria-Bertani (LB) broth with 100 g/ml
mpicillin and 50 g/ml of chloramphenicol, shaking at 225 rpm.
he cultures were back diluted 1:20 24 h later and grown to an
D600 between 0.8 and 1.0. Protein expression was induced with
sopropyl 1 mM -d-1 thiogalactopyranoside (IPTG). Cells were
entrifuged at 5000 g for 5 min  at 4 ◦C and resuspended in Lysis
uffer [30] and Complete, EDTA-free Protease Inhibitor Cocktail
ablet (Roche)), incubated at 25 ◦C for 30 min  and then at 37 ◦C for
0 min, shaking at 225 rpm.
The soluble fraction containing the E2wt monomers was  recov-
red after centrifugation at 10,000 g for 10 min  at 4 ◦C and loaded
nto a Sephadex G-25 column (GE Healthcare) for buffer exchange.
ractions containing E2wt were pooled and loaded onto a Detoxi-
el column (Pierce), with E2wt recovered in the ﬂow through,
hich was then loaded onto a Q-Sepharose anion exchange column
GE Healthcare). Bound protein was eluted from the column with
 0–60%/400 ml  gradient of elution buffer [30]. Peak fractions con-
aining E2wt were pooled and concentrated with a 10 kD molecular
eight cut off (MWCF) using Amicon Ultra Centrifugal Filter (Mil-
ipore). The retentate was loaded onto a Superdex200 gel ﬁltration
olumn (GE Healthcare) using Solubility Buffer 2.2 [30]. Fractions
ontaining the 1.5 MDa  E2wt 60-mer particles were concentrated
o 1 mg/ml  using the Ultra Centrifugal devices and then stored in
olubility Buffer 2.2 at −80 ◦C.
The recombinant protein vaccine component consists of EDIII-
2 protein alone, without E2wt. To prepare the vaccine protein,
DIII-E2 protein containing inclusion bodies from Escherichia coli
ere puriﬁed from the insoluble fraction following bacterial lysis
nd centrifugation at 10,000 g for 10 min  at 4 ◦C, washed three
imes with Inclusion Body Wash Buffer [30] and allowed to unfold
n Unfolding Buffer (6 M GuHCl, 1 mM DTT, in PBS) [30] rocking
t 4 ◦C for a minimum of 3 h. Solubilized inclusion body proteins
ere transferred to SnakeSkin dialysis tubing, 10 K MWCO  (Pierce)
nd subjected to step-down dialysis against the buffers as previ-
usly described [30]. As a ﬁnal puriﬁcation step, refolded soluble
DIII-E2 60 mer  particles were loaded onto a Superdex200 col-
mn  (GE Healthcare) to buffer exchange into PBS, and purity and
dentity were assessed by SDS-PAGE and Western blot analysis,
espectively. LPS was not removed from the preparation, as we
ave previously found no difference in E2 immunogenicity in the
resence or absence of LPS [29].
.3. SDS-PAGE and Western blot analysis
Expression, refolding, and identity of recombinant proteins
ere assessed by SDS-PAGE and Western blot analysis using
nvitrogen NuPAGE 4–12% Bis-Tris mini-gels (Carlsbad, CA) under
educing conditions. For SDS-PAGE, gels were stained with Sim-
lyBlue SafeStain (Invitrogen). For Western blot analysis, proteins
ere transferred onto nitrocellulose paper (Invitrogen), blocked
ith Odyssey blocking buffer (LI-COR Biosciences) overnight at
◦C. The following day, the blot was probed simultaneously with
erum from a rabbit immunized with E2wt (1:8000) and the mouse
Abs 8A5 (1:2000) for 1 h at 25 ◦C. Primary Abs were prepared
n Odyssey Blocking Buffer 1:1 with 1× PBS, 0.2% Tween-20. Blots
ere washed 5 times with 0.1% Triton X-100, 1× PBS. Secondary 34 (2016) 3500–3507
Abs IRDye 680 Goat anti-Rabbit and IRDye 800CW Goat anti-mouse
(LI-COR Biosciences) were used at 1:15,000, diluted in Odyssey
Blocking Buffer 1:1 with 1× PBS, 0.2% Tween-20, 0.02% SDS. Mem-
branes were scanned using the LI-COR Odyssey Infrared Imaging
System (LI-COR Biosciences) to detect E2 and the DENV EDIII
simultaneously. Integrated intensities were used with protein con-
centrations (NanoDrop Technologies, Wilmington DE) to calculate
protein purity and concentration.
2.4. Biosensor analyses
Surface plasmon resonance (SPR) biosensor assays were carried
out at 25 ◦C using the Biacore X100 instrument (GE Healthcare, Pis-
cataway, NJ). 10 g/ml of E2wt or EDIII-E2 particles were diluted
in sodium acetate buffer (pH 5.5) and immobilized by standard
coupling chemistry on a CM3  sensor chip. E2wt and EDIII-E2 par-
ticles were immobilized to a level of 60 RU on ﬂow cell 2 and 3,
respectfully. Flow cell 1 was activated and blocked and its response
was subtracted from all other ﬂow cells. Binding experiments were
carried out by injecting the monoclonal Abs 8A5 over the sensor
surface at varying concentrations in HBS-EP buffer (10 mM HEPES,
150 mM NaCl, 1 mM EDTA, 0.05% P20) at a ﬂow rate of 30 l/min for
5 min. Following a 10-min dissociation phase, the chip surface was
regenerated for each concentration of injected Ab with a 45 s pulse
of 10 mM glycine, pH 2.5. Additionally mAb  DVC 3.7, DVC 10.16 and
DVC 14.2 were tested at a single concentration of 33.3 nM.  All data
were double reference subtracted with buffer blank injections. Data
were processed using X100 evaluation software.
2.5. Enzyme-linked immunosorbent assay (ELISA)
Binding Ab responses from individual macaques to the E2wt
protein and EDIII were measured by ELISA as described previously
[38]. Endpoint titers were calculated as the lowest positive value for
each sample that was three-times the average background of pre-
immune macaque serum included in triplicate per plate. Individual
polypeptides were added (0.05 ml at 0.01 mg/ml) to ﬂat-bottom
96-well plates (Thermo Scientiﬁc), and incubated overnight at 4 ◦C.
Plates were blocked with Blotto (PBS, 5% nonfat dry milk, 1% goat
serum) for 1 h, serum added and incubated for 1 h at 25 ◦C and
washed ﬁve times with Wash Buffer (PBS, 0.1% Trition X-100). Goat
anti-human IgG-HRP at 1:4000 in Disruption Buffer (PBS, 5% FBS,
2% BSA, 1% Trition X-100) was added to the plate and incubated
for one hour at 25 ◦C. The plates were washed, and TMB  substrate
(Sigma) was added to each well and incubated for 30 min  in the
dark. The reaction was stopped and the plates were read at 450 nm
(Molecular Devices SpectraMax 190). Optical density (OD) values
were calculated for each sample.
2.6. Production of dengue viral stocks
DENV2 strains 16681 was  derived from the DENV2 16681 infec-
tious clone [33]. Strain 16803 was  generously provided by Aravinda
de Silva, UNC Chapel Hill. Viruses were propagated in Aedes albopic-
tus C6/36 cells at 32 ◦C 5% CO2 in MEM  (Cellgro) supplemented
with 5% fetal bovine serum (FBS), non-essential amino acids (Cell-
gro) and antibacterial-antifungal mix  (Gibco anti-anti). Virus was
applied to 80–90% conﬂuent monolayers at an approximate multi-
plicity of infection (MOI) of 0.01 and incubated for 5–7 days. Culture
supernatants were harvested, clariﬁed by centrifugation and frozen
at −80 ◦C in 10% sucrose-phosphate-glutamic acid (SPG) buffer.2.7. Focus assays
The focus is based on a method previously described by White-
head [34]. Brieﬂy, twenty-four well plates were seeded with 5 × 104
accine 34 (2016) 3500–3507 3503
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Fig. 2. Structural analysis of EDIII-E2 particles by Surface Plasmon Resonance.
EDIII-E2 and E2 only particles were immobilized on the surface of a Biacore chip.
Conformational antibodies were ﬂowed over the surface of the chip to determine
the availability of antibody binding sites. (A) 8A5 was tested at increasing concen-
trations. Binding is shown as RUs over injection time. (B) Antibodies DVC 3.7, DVC
10.16, and DVC 14.2 were tested 3 times at 33.3 nM.  Results are shown as Max  RUsS.P. McBurney et al. / V
ero cells in MEM  supplemented with 5% fetal bovine serum (FBS)
nd grown for 24 h. Growth media was removed. For virus titration,
irus stocks were diluted serially ten-fold and added to individ-
al wells. Cells were overlaid with 1 ml  0.8% methylcellulose in
ptiMEM (Gibco) supplemented with 2% FBS (Cellgro) and antibi-
tic mix  (Gibco Anti-Anti) and incubated 5 days at 37 ◦C, 5% CO2.
n day 5, overlay was removed, cells washed with PBS, ﬁxed in
0% methanol and developed. To develop plates, ﬁxed monolayers
ere blocked with 5% instant milk PBS, followed by incubation
ith anti-ﬂavivirus MAb  4G2 diluted 1:1000. Wells were washed
ith PBS and incubated with horseradish peroxidase (HRP) conju-
ated goat anti-mouse Ab (Sigma) diluted 1:500 in blocking buffer
or 1 h at 37 ◦C. Plates were washed once in PBS and foci devel-
ped by the addition of 100 l of TrueBlue HRP substrate (KPL).
oci were counted on a light box and viral titers calculated by
tandard methods. For focus reduction neutralization test (FRNT),
rimate sera were serially diluted from starting dilutions of 1:10,
ixed with equal volume media containing approximately 50 focus
orming units (ffu) of virus to a ﬁnal volume of 200 l, incubated
or 1 h at 37 ◦C, 5% CO2 and added in triplicate to 24 wells plates
nd processed as above. For delayed focus assay, 150 L of acute
acaque sera were inoculated onto 90% conﬂuent C6/36 cells in
-25 ﬂasks and incubated for 7 days at 32 ◦C, 5% CO2. On day 7,
upernatants were harvested and titrated as described above. The
nal readout for the delayed focus assay is presence (+) or absence
−) of detectable virus.
.8. Dengue virus challenge
Six vaccinated macaques (EDIII-E2) and three naïve macaques
ere challenged with 5 × 105 FFU DENV2 isolate 16803 at ﬁve
eeks following the ﬁnal vaccination. Challenged was delivered
y 0.2 ml  intramuscular injection in the quadriceps muscle. Serum
amples were collected at the time of viral challenge and daily for
he ﬁrst ten days post-challenge and at day 21 days post-infection.
.9. RNA isolation and quantiﬁcation
Blood specimens collected on days 0 through 10 were assayed
or viral RNA by routine and quantitative PCR. QiaAmp Viral RNA
ini Kit (QIAGEN, Valencia, CA) was used to extract viral RNA
rom primate sera following the manufacturer’s protocol. Extracted
NA was immediately subjected to routine RT-PCR as previously
escribed [35]. RNA from PCR positive serum samples were subse-
uently subjected to single reaction real-time RT-PCR as previously
escribed [36] using an Applied Biosystems Step-One Plus thermo-
ycler (Forest City, CA).
. Results
.1. Recombinant EDIII-E2 fusion protein preserves EDIII
onformational epitopes
The EDIII-E2 fusion protein was expressed in E. coli and puri-
ed from inclusion bodies as described above. Protein expression
n whole cell lysate was analyzed by SDS-PAGE (Fig. 1A) and co-
ocalization of E2 and EDIII demonstrated by western blot using
oth E2 speciﬁc and EDIII speciﬁc antibodies (Fig. 1A). The vaccine
onstruct was then puriﬁed from E. coli inclusion bodies by centrifu-
ation, solubilization and dialysis, and gel ﬁltration as described in
aterials and Methods and evaluated by SDS-PAGE with results
howing that the resulting protein is >95% pure (Fig. 1B). EDIII
xpression by the pEMC* based DNA component of the vaccine of
he EDIII insert was veriﬁed by western blot (Fig. 1C).
Conformational EDIII epitopes on the surface of the EDIII-E2
article was determined by surface plasmon resonance (SPR). Thefrom each run.
conformation-dependent mouse monoclonal antibody (mAb) 8A5
and human conformational EDIII speciﬁc mAbs (DVC 3.7, DVC 10.16
and DVC 14.21 [15,37] were tested against the E2 and EDIII-E2 parti-
cles with speciﬁc antibody binding only observed with the EDIII-E2
particle (Fig. 2A and B), collectively demonstrating known epitopes
on the EDIII-E2 particle are accessible and displayed in a native
conformation.
3.2. The EDIII-E2/DNA vaccine is highly immunogenic
EDIII-E2 puriﬁed particles were delivered intramuscularly at the
same time that EDIII DNA expression plasmid and IL-12 DNA was
delivered intradermally by gene gun at weeks 0, 4, and 12. Anti-
body responses to the E2 particle and EDIII were ﬁrst evaluated
by ELISA (Fig. 3A and B). Strong and rapid antibody responses to
the E2 carrier particle were observed following the prime dose
with endpoint antibody titers reaching 1:100,000 (Fig. 3A). Anti-
EDIII binding antibody response was also detected following the
prime dose (Fig. 3B) and were subsequently boosted, reaching
a ﬁnal endpoint titer of 1:100,000 by the third dose. Neutral-
izing (FRNT50) titers against DENV2 16681 > 1:20 were detected
after the second vaccination (Fig. 3C) and were further boosted
following the third vaccination. Tests of the breadth of neutral-
ization against heterologous serotypes found little to no cross
neutralization (Fig. 4). Overall the EDIII-E2/DNA EDIII vaccine
elicited a narrow, highly serotype speciﬁc neutralizing antibody
response.
3504 S.P. McBurney et al. / Vaccine 34 (2016) 3500–3507
14121086420
101
102
103
104
105
Wee k 
F
R
N
T
5
0
 
DENV-2 ne utrali zing  an tibod y res pon se
EDIII  antibod y respo nse
14121086420
102
103
104
105
106
107
Wee k
E
n
d
p
o
in
t 
ti
te
r 
14121086420
102
103
104
105
106
107
Wee k 
E
n
d
p
o
in
t 
ti
te
r 
E2 antibody  respon se BA
C
26626*
27350
27733*
27758*
27772
27923
Fig. 3. Antibody responses induced by EDIII-E2/EDIII DNA vaccination. Antibody responses were determined from serum samples obtained at the time of the ﬁrst vaccination,
and  then two weeks following each vaccination. Dotted lines represent limits of detection for each of the assays. Dilutions of serum samples were tested for binding to E2
( ples 
1 nimal
i to the
3
c
g
s
i
b
a
d
t
p
P
R
m
b
r
a
h
T
DA)  and E (B) by ELISA. Results are reported as endpoint titer. Dilutions of serum sam
6681 virus(C). Results are reported as FRNT50 titer. Red ﬁlled symbols indicate a
nterpretation of the references to color in this ﬁgure legend, the reader is referred 
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hallenge
Vaccinated and naïve macaques were challenged with heterolo-
ous DENV2 strain 16803 5 weeks after the ﬁnal vaccination. Serum
amples were obtained daily from day 0–10 post-challenge to ver-
fy viral clearance and day 21 to measure the early post-challenge
oosting. Serum viremia was ﬁrst determined by delayed focus
ssay (Table 1). Naïve macaques had detectable infectious virus by
ay two post-challenge with a duration range of 2–7 days. None of
he vaccinated group had detectable infectious virus at any point
ost-challenge. The presence of viral RNA was determined by RT-
CR and RT-qPCR (Fig. 5A). All naïve controls had detectable dengue
NA for 8–9 days. DENV2 RNA was detected in 3 of 6 vaccinated
acaques, with onset and duration of viral RNA trending toward
eing later and shorter than that observed for naïve animals. The
emaining 3 vaccinees had no evidence of DENV2 infection.
FRNT50 titers against the challenge strain16803 were measured
t d0 and d21 post-infection. All macaques in the vaccine group
ad FRNT50 titers of greater that 1:1,000 at the time of challenge on
able 1
ENV 16803 Challenge-Detectable Viremia by delayed focus assay.
Group NHP Day post infection
1 2 3 4 
EDIII-E2
26626 − − − − 
27350 − − − − 
27733 − − − − 
27758 − − − − 
27772 − − − − 
27923 − − − − 
Naive
26764 − − + + 
28504 − − + + 
29445 − − + + were also tested for neutralizing antibodies by FRNT assay against matched DENV2
s that were PCR positive on DENV2 challenge, green ﬁlled are PCR negative. (For
 web  version of this article.)
week 17 (Fig. 5B). At day 21 post-challenge the PCR positive animals
had a 10–30 fold boost in titer boost in FRNT50 titer (Fig. 5A and C),
while FRNT50 titers for the PCR negative macaques remained con-
stant, indicating that the EDIII-E2 vaccine had induced sterilizing
immunity in these three animals (Fig. 5D). Week 17 antibody titers
>1:6000 against 16681 in the vaccinated macaques was associated
with sterilizing immunity that provided absolute protection against
challenge with 16803 (Fig. 6A). Week 17 antibody titers against
16681 were signiﬁcantly negatively associated with days viremic in
the vaccinated macaques (Spearman r = −0.94, P < 0.0001) (Fig. 6B).
Week 17 FRNT50 titers against the challenge strain 16803, were also
negatively correlated with days viremic (Spearman r = −0.58) but
the relationship was not statistically signiﬁcant (P = 0.20, data not
shown).4. Discussion
Several candidate DENV vaccines are under development, the
most advanced of which is the LAV CYD-TDV vaccine [9]. However,
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serotype [9]. Limited immunogenicity because of viral interference
and immunodominance (or inferiority) of individual serotypes are
hypothesized to play a role in the variable results of these trials
[38,39], and other LAV based approaches are expected to face sim-
ilar hurdles. Non-LAV vaccines offer an alternate strategy that may
have the potential to overcome these LAV challenges.
Here we  show that recombinant DENV2 EDIII displayed on a
protein scaffold preserves native DENV2 epitopes and is highly
immunogenic in macaques when delivered with EDIII express-
ing DNA. Using infectious virus assays, qPCR and antibody boost
post challenge, we  observed two  distinct protection outcomes
in this study. First, we found evidence for sterilizing immunity
in three vaccinated macaques while the remaining three vacci-
nated macaques were partially protect, as while we did not detect
challenge virus via infectious assay, we detected viral RNA by
qPCR and observed a neutralization titer boost, both suggest-
ing viral replication after challenge. These results highlight the
importance of using all three post-challenge methodologies in
order to comprehensively characterize vaccine-induced protective
immunity, especially in the NHP models where disease is not man-
ifested.
We observed a signiﬁcant correlation between week 17 FRNT50
and days viremia on challenge. Week 17 FRNT50 titer against
parental strain 16681 was also predictive of sterile versus anamnes-
tic immunity: the three macaques with FRNT50 titers > 1:6000 were
sterilely protected whereas the three with FRNT50 titers < 1:6000
had detectable viral RNA by qPCR (Fig. 6) and a boost in 21 day
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ost-challenge FRNT50 titer (Fig. 5C). This result suggests that an
RNT50 threshold of protection on challenge is around 1:6000
Fig. 6). While these FRNT50 titers associated with sterilizing immu-
ity are considerably higher than what have been observed as a
terilizing protective neutralization threshold for humans vacci-
ated with LAV DENV vaccines [40], following natural infection
41] they are only two-fold greater than what has been observed
or other vaccinated NHPs [42]. These ﬁndings suggest that recom-
inant protein vaccine-induced neutralizing antibodies may  differ
rom antibodies raised by natural infection or LAV vaccination and
hat higher neutralizing antibody titers may  have to be achieved
y recombinant protein vaccines in macaques to establish steriliz-
ng protection. However, caution should be taken when translating
hresholds of protection for primates to human thresholds of pro-
ection. This point is further emphasized by the ﬁnding that while
eek 17 FRNT titers against the parent strain 16681 did signiﬁ-
antly correlate with sterilizing immunity, Week 17 FRNT50 titers
gainst the challenge strain 16803 did not signiﬁcantly correlate
ith sterilizing immunity (Fig. 4B). This discrepancy may  be the
ffect of the small number of animals in the study (n = 6), differences
n speciﬁc strain sensitivity to neutralization, or the unmeasured
ontribution of cellular immunity induced by the DNA component
f the vaccine.
The E2 platform we describe here has the potential to be devel-
ped into a tetravalent DENV vaccine. Intriguingly, multimeric E2
LP can be assembled either using a cocktail of E2 monomers
isplaying each of the four EDIIIs or a refolded multi-serotype
accine containing VLPs assembled from each individual serotype.
ritically, we have identiﬁed, for this vaccine platform, the approx-
mate threshold antibody required for sterilizing immunity against
ENV2 in macaques, allowing vaccine evaluation to proceed with
 clear endpoint. 34 (2016) 3500–3507
A challenge faced by all current dengue vaccine approaches is
inducing a robust and sustained neutralizing antibody response
against all four dengue serotypes, lest the vaccine induce ADE asso-
ciated severe dengue disease as antibody titers wane. This may  have
been observed in the recent CYD-TDV trials, with increased hospi-
talization observed in the vaccine arm in children aged <9 yrs [9].
One other DENV LAV vaccine, TV003, developed by the Laboratory
of Infectious Diseases/National Institute of Allergy and Infectious
Diseases (LID/NIAID) [43–45] has now entered phase 3 human tri-
als (NCT02406729). In a recently published pre-phase 3 study [46],
TV003 vaccines were challenged with a live attenuated DENV2
strain 6 months post vaccination (N = 21) with 43% (9 of 21) show-
ing a four-fold or greater boost in NAb titer post challenge. As with
our challenge, the authors did not ﬁnd infectious virus by tissue
culture in the vaccinees, but the presence of a memory boost in
9 of 21 vaccinees suggests virus replication likely occurred, as we
observed in our study.
While our monovalent formulation initially induced robust neu-
tralizing antibodies in non-human primates, these titers waned
to below a sterilizing titer in three of six animals in 5 weeks, a
result that would need to be overcome by an effective tetravalent
EDIII/DNA vaccine. To address this fundamental concern, several
avenues for further investigation need to be undertaken, including:
assessing whether recently described quaternary epitopes recog-
nized by type speciﬁc or broadly neutralizing DENV antibodies
[47–53] could be displayed on the E2 scaffold and induce a more
sustained antibody response; establishing the role of adjuvants in
inducing neutralizing antibodies in the context of E2/DNA vacci-
nation; more clearly establishing the relative contributions of the
recombinant protein and DNA components of the vaccine formu-
lation to protection; assessing the contribution of cell-mediated
immunity to protection conferred by the E2/DNA vaccine plat-
form; assessing the kinetics of decay over a longer period of time
for tetravalent E2/DNA vaccine formulations; and evaluating the
potential for antibody enhanced disease as neutralizing titers wane
following tetravalent vaccination.
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